Purpose <p>To develop a [<sup>18</sup>F]fluorodeoxyglucose ([<sup>18</sup>F]FDG) positron emission tomography (PET) primary tumor radiomic model for predicting disease-specific survival (DSS), and compare it with conventional PET markers in a large endometrial cancer cohort.</p> Methods <p>Radiomic features were extracted from preoperative [<sup>18</sup>F]FDG PET scans of 489 endometrial cancer patients using a standardized uptake value (SUV) threshold &gt; 2.5 to define primary metabolic tumor volumes (MTVs). A second reader extracted features in 154/489 patients, in which intraclass correlation coefficients (ICCs) were calculated. Radiomic features with ICCs &gt; 0.75 were retained and ComBat harmonization was applied to reduce scanner/protocol effects on the extracted features. Patients were divided into training (<i>n</i> = 343) and test (<i>n</i> = 146) sets. A radiomic DSS score (R<sub>dss</sub>) was developed in the training set using least absolute shrinkage and selection operator (LASSO) Cox regression. A combined model (C<sub>dss</sub>), incorporating R<sub>dss</sub>, PET positive lymph nodes (LN<sub>PET</sub>) and preoperative histology risk was constructed using multivariable Cox hazard analyses. Prediction performances were assessed by comparing areas under time-dependent receiver operating characteristic curves (tdROCs AUCs) for R<sub>dss</sub>, C<sub>dss</sub>, and conventional PET markers: SUV<sub>max</sub>, SUV<sub>mean</sub>, MTV, tumor lesion glycolysis (TLG) and LN<sub>PET</sub>.</p> Results <p>In the test set, AUCs for 2- and 5-year DSS were higher for R<sub>dss</sub> (0.855, 0.720) compared to SUV<sub>max</sub> (0.548, 0.572) and SUV<sub>mean</sub> (0.549, 0.554) (<i>p</i> ≤ 0.04 for all), while similar to MTV (0.863, 0.696), TLG (0.814, 0.672) and LN<sub>PET</sub> (0.802, 0.626) (<i>p</i> ≥ 0.12 for all). C<sub>dss</sub> predicted 2-year DSS with AUC of 0.909 in the test set, outperforming all conventional imaging markers (<i>p</i> ≤ 0.04 for all) except MTV (<i>p</i> = 0.29). For 5-year DSS, C<sub>dss</sub> (AUC: 0.817) outperformed all conventional imaging markers, including MTV (AUC ≤ 0.696, <i>p</i> ≤ 0.05, for all).</p> Conclusion <p>R<sub>dss</sub> predicts short-term survival with high accuracy, outperforming tumor SUV<sub>max/mean</sub>, but not MTV, TLG and LN<sub>PET</sub>. The combined C<sub>dss</sub> model yields high accuracy for predicting both short- and long-term survival, outperforming all conventional PET imaging markers.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Predicting aggressive disease and poor outcome in endometrial cancer using preoperative [18F]FDG PET primary tumor radiomics

  • Kristine Eldevik Fasmer,
  • Ankush Gulati,
  • Sunniva Lindås,
  • Camilla Krakstad,
  • Ingfrid Salvesen Haldorsen

摘要

Purpose

To develop a [18F]fluorodeoxyglucose ([18F]FDG) positron emission tomography (PET) primary tumor radiomic model for predicting disease-specific survival (DSS), and compare it with conventional PET markers in a large endometrial cancer cohort.

Methods

Radiomic features were extracted from preoperative [18F]FDG PET scans of 489 endometrial cancer patients using a standardized uptake value (SUV) threshold > 2.5 to define primary metabolic tumor volumes (MTVs). A second reader extracted features in 154/489 patients, in which intraclass correlation coefficients (ICCs) were calculated. Radiomic features with ICCs > 0.75 were retained and ComBat harmonization was applied to reduce scanner/protocol effects on the extracted features. Patients were divided into training (n = 343) and test (n = 146) sets. A radiomic DSS score (Rdss) was developed in the training set using least absolute shrinkage and selection operator (LASSO) Cox regression. A combined model (Cdss), incorporating Rdss, PET positive lymph nodes (LNPET) and preoperative histology risk was constructed using multivariable Cox hazard analyses. Prediction performances were assessed by comparing areas under time-dependent receiver operating characteristic curves (tdROCs AUCs) for Rdss, Cdss, and conventional PET markers: SUVmax, SUVmean, MTV, tumor lesion glycolysis (TLG) and LNPET.

Results

In the test set, AUCs for 2- and 5-year DSS were higher for Rdss (0.855, 0.720) compared to SUVmax (0.548, 0.572) and SUVmean (0.549, 0.554) (p ≤ 0.04 for all), while similar to MTV (0.863, 0.696), TLG (0.814, 0.672) and LNPET (0.802, 0.626) (p ≥ 0.12 for all). Cdss predicted 2-year DSS with AUC of 0.909 in the test set, outperforming all conventional imaging markers (p ≤ 0.04 for all) except MTV (p = 0.29). For 5-year DSS, Cdss (AUC: 0.817) outperformed all conventional imaging markers, including MTV (AUC ≤ 0.696, p ≤ 0.05, for all).

Conclusion

Rdss predicts short-term survival with high accuracy, outperforming tumor SUVmax/mean, but not MTV, TLG and LNPET. The combined Cdss model yields high accuracy for predicting both short- and long-term survival, outperforming all conventional PET imaging markers.